Chemistry:Motugivatrep
From HandWiki
Motugivatrep (brand name Avarept) is an ophthalmic drug. In Japan, it is approved to treat dry eye disease.[1]
It acts as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist.[2]
References
- ↑ "Approval in Japan for Avarept Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition". December 22, 2025. https://firstwordpharma.com/story/6861155.
- ↑ "Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study". American Journal of Ophthalmology 283: 163–175. December 2025. doi:10.1016/j.ajo.2025.11.036. PMID 41352685.
 |  |
